Jennifer Carver
Director/Board Member at REVELATION BIOSCIENCES, INC.
Net worth: 290 $ as of 2024-03-30
Profile
Jennifer Carver is currently a Director at Revelation Biosciences Sub, Inc. and an Independent Director at Revelation Biosciences, Inc. She previously worked as a Senior Director-Project Management at Spectrum Pharmaceuticals, Inc. from 2012 to 2014, as a Project Manager-Folotyn at Allos Therapeutics, Inc. from 2001 to 2012, and as the Chief Operating Officer at La Jolla Pharmaceutical Co. from 2017 to 2019.
She also briefly served as the Chief Operating Officer at Kartos Therapeutics, Inc. in 2020 and 2021.
Ms. Carver received her undergraduate degree and MBA from The University of Colorado.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-17 | 106 ( 0.01% ) | 290 $ | 2024-03-30 |
Jennifer Carver active positions
| Companies | Position | Start |
|---|---|---|
| REVELATION BIOSCIENCES, INC. | Director/Board Member | 2020-04-30 |
Revelation Biosciences Sub, Inc.
 Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The private company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | Director/Board Member | - |
Former positions of Jennifer Carver
| Companies | Position | End |
|---|---|---|
Kartos Therapeutics, Inc.
 Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | Chief Operating Officer | 2020-12-31 |
| LA JOLLA PHARMACEUTICAL COMPANY | Chief Operating Officer | 2019-11-22 |
| SPECTRUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2013-12-31 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Corporate Officer/Principal | 2011-12-31 |
Training of Jennifer Carver
| The University of Colorado | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
La Jolla Pharmaceutical Co.
 La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | Health Technology |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The private company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | Health Technology |
| Revelation Biosciences, Inc. |
- Stock Market
- Insiders
- Jennifer Carver
